Agilent Technologies (bioanalytical and electronic measurement instruments) is paying $10.94 in cash per share (a 31% premium) to acquire diagnostics and research tools maker Stratagene in a transaction valued at about $246mm based on 22.4mm Stratagene shares outstanding. (April)
Agilent plans to make Stratagene a division of its Life Sciences Solutions Unit. Stratagene, which started operations in 1984, serves government, academic, and industrial markets. Its reagents, instruments, and other...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?